United States v. Daniel Gwin

CourtCourt of Appeals for the Sixth Circuit
DecidedMarch 14, 2024
Docket23-3465
StatusUnpublished

This text of United States v. Daniel Gwin (United States v. Daniel Gwin) is published on Counsel Stack Legal Research, covering Court of Appeals for the Sixth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Daniel Gwin, (6th Cir. 2024).

Opinion

NOT RECOMMENDED FOR PUBLICATION File Name: 24a0120n.06

No. 23-3465 FILED UNITED STATES COURT OF APPEALS Mar 14, 2024 FOR THE SIXTH CIRCUIT KELLY L. STEPHENS, Clerk ) UNITED STATES OF AMERICA, ) ON APPEAL FROM THE Plaintiff-Appellee, ) UNITED STATES DISTRICT ) COURT FOR THE v. ) NORTHERN DISTRICT OF ) OHIO DANIEL GWIN, ) Defendant-Appellant. ) OPINION )

Before: COLE, CLAY, and BLOOMEKATZ, Circuit Judges.

BLOOMEKATZ, Circuit Judge. In 2022, Daniel Gwin pleaded guilty to nine felony counts

stemming from his role in a conspiracy at his workplace. Gwin was a manager at a family-owned

medical research center that we refer to as “Company 1.” Gwin, along with seven other Company

1 employees, fabricated the results of clinical trials for recently developed medications, which

pharmaceutical companies then presented to federal regulators in seeking approval to make these

new drugs available to the public.

The district court sentenced Gwin to a below-guidelines sentence of 30-months’

imprisonment. Gwin claims that this sentence was both procedurally and substantively

unreasonable, arguing that the district court did not sufficiently explain why it sentenced him to

several more months than two of his coconspirators, and that it did not adequately weigh the

mitigating factors which, in his view, mandated a lesser sentence. Because the district court did

not abuse its discretion in sentencing Gwin, we affirm. No. 23-3465, United States v. Gwin

FACTUAL BACKGROUND

In 2012, Daniel Gwin began a position as a study coordinator at Company 1. Company 1

was a research organization owned by Amie Demming and Debra Adamson—a mother and

daughter team—with offices in Ohio and Tennessee. The company employed multiple family

members, including William and Ashley Adamson, but Gwin was not related. Company 1

conducted FDA-required clinical trials of investigative drugs for pharmaceutical companies.

Clinical trials are necessary to ensure that a pharmaceutical company’s new drug is safe and

effective for human use. As a study coordinator in the Cleveland-area office, Gwin was responsible

for managing the trials for various of Company 1’s clients, and in doing so he supervised other

research employees.

The conspiracy began in 2013, about six months after Gwin took the job. Demming was

the ringleader and developed the scheme when the company began to face financial troubles. Gwin

states that Demming harassed, bullied, and intimidated him, and that he feared losing his job if he

did not participate in the scheme.

The scheme, roughly described, was as follows: Company 1 employees falsely inflated the

number of research participants in the clinical trials, then Company 1 billed its clients for the

nonexistent work. Gwin and his colleagues fabricated test subjects from whole cloth, registered

patients for studies without consent, falsified laboratory results, and collected payment for each

phony participant. At times, Gwin even substituted his own blood and medical information for that

of real study participants. As a study coordinator, Gwin signed informed consent forms for other

employees who fraudulently registered themselves in clinical trials. Company 1 sent these false

clinical results to its pharmaceutical clients, who then submitted the results to the FDA in seeking

approval that their drugs were safe and effective.

-2- No. 23-3465, United States v. Gwin

Because Gwin’s claim rests on the alleged sentencing disparity with his coconspirators, we

describe not only his culpability, but also that of William and Ashley Adamson, whom Gwin points

to as the most relevant comparators. William and Ashley Adamson were Amie Demming’s brother

and sister-in-law, and they managed the Tennessee offices.

The three employees were responsible for similar amounts of economic loss. During the

course of the conspiracy, eight pharmaceutical companies paid Company 1 a total of $6,552,903

for—unbeknownst to them—fraudulent clinical trials. Gwin was personally responsible for little

over $2.8 million of that amount, the third highest of the defendants. William Adamson caused

$2.72 million in loss and Ashley Adamson caused $2.94 million in loss.

The three employees were also paid under a similar compensation structure. Company 1

paid Gwin and the Adamsons an annual salary and a year-end bonus. The bonus was based on the

company’s profits and the employee’s individual performance, which was tied to the number of

patients the employee enrolled in studies. Gwin had a starting salary of $43,500, and Ashley

Adamson, who began around the same time, had a starting salary $41,600. No party argued that

their salaries differed markedly in subsequent years. In their first years, Gwin and Ashley Adamson

received bonuses of $500 and $1,800, respectively, while the next year they received $1,500 and

$1,800, respectively.

The three employees’ pleas, however, looked different. The Adamsons pleaded guilty to

one count of conspiracy to commit mail fraud and wire fraud. The district court sentenced William

to 22 months’ imprisonment and Ashley to 27 months.

Gwin pleaded guilty to nine counts—one count of conspiracy to commit mail fraud and

wire fraud, seven counts of mail fraud, and one count of conspiracy to defraud the United States.

At sentencing, the court granted Gwin a three-level reduction for acceptance of responsibility.

-3- No. 23-3465, United States v. Gwin

That, combined with Gwin’s lack of criminal history, resulted in a range of 33 to 41 months under

the Sentencing Guidelines. After weighing the aggravating and mitigating factors, the district court

varied downward, giving Gwin a below-guidelines sentence of 30-months in prison followed by

three years of supervised release, a mandatory $900 special assessment, and $2,841,792 in

restitution.

ANALYSIS

On appeal, Gwin argues that his sentence was both procedurally and substantively

unreasonable. We review both his procedural and substantive reasonableness claims for an abuse

of discretion. Gall v. United States, 552 U.S. 38, 41 (2007).1 We address each challenge in turn.

I. Procedural Reasonableness In reviewing whether a sentence was procedurally unreasonable, we look to see whether

the district court “(1) properly calculated the applicable advisory Guidelines range; (2) considered

the other § 3553(a) factors as well as the parties’ arguments for a sentence outside the Guidelines

range; and (3) adequately articulated its reasoning for imposing the particular sentence chosen,

including any . . . decision to deviate from the advisory Guidelines range” or rejection of the

parties’ arguments that it should deviate. United States v. Bolds, 511 F.3d 568, 581 (2007).

Gwin urges us to reverse on the third requirement, arguing that the district court did not

adequately articulate why he received a longer sentence than either William or Ashley Adamson.

He emphasizes that he received the second highest sentence in the conspiracy—just behind

1 The government urges us to review the procedural reasonableness claim for plain error rather than for an abuse of discretion because it says that Gwin did not adequately preserve his objection at the sentencing hearing.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gall v. United States
552 U.S. 38 (Supreme Court, 2007)
United States v. Algis J. Gale
468 F.3d 929 (Sixth Circuit, 2006)
United States v. Thomas Greco, Jr.
734 F.3d 441 (Sixth Circuit, 2013)
United States v. Bolds
511 F.3d 568 (Sixth Circuit, 2007)
United States v. Wallace
597 F.3d 794 (Sixth Circuit, 2010)
United States v. Duane
533 F.3d 441 (Sixth Circuit, 2008)
United States v. Conatser
514 F.3d 508 (Sixth Circuit, 2008)
United States v. Rufus Robinson
778 F.3d 515 (Sixth Circuit, 2015)
United States v. Keelan Harris
636 F. App'x 922 (Sixth Circuit, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
United States v. Daniel Gwin, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-daniel-gwin-ca6-2024.